@article{BuschNadalSchmidetal.2016,
  author    = {Busch, Martin and Nadal, Jennifer and Schmid, Matthias and Paul, Katharina and Titze, Stephanie and H{\"u}bner, Silvia and K{\"o}ttgen, Anna and Schultheiss, Ulla T. and Baid-Agrawal, Seema and Lorenzen, Johan and Schlieper, Georg and Sommerer, Claudia and Krane, Vera and Hilge, Robert and Kielstein, Jan T. and Kronenberg, Florian and Wanner, Christoph and Eckardt, Kai-Uwe and Wolf, Gunter},
  title     = {Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease - cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort},
  series = {BMC Nephrology},
  volume    = {17},
  journal   = {BMC Nephrology},
  number    = {59},
  doi       = {10.1186/s12882-016-0273-z},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-164687},
  year      = {2016},
  abstract  = {Background Diabetes mellitus (DM) is the leading cause of end-stage renal disease. Little is known about practice patterns of anti-diabetic therapy in the presence of chronic kidney disease (CKD) and correlates with glycaemic control. We therefore aimed to analyze current antidiabetic treatment and correlates of metabolic control in a large contemporary prospective cohort of patients with diabetes and CKD. Methods The German Chronic Kidney Disease (GCKD) study enrolled 5217 patients aged 18-74 years with an estimated glomerular filtration rate (eGFR) between 30-60 mL/min/1.73 m2 or proteinuria >0.5 g/d. The use of diet prescription, oral anti-diabetic medication, and insulin was assessed at baseline. HbA1c, measured centrally, was the main outcome measure. Results At baseline, DM was present in 1842 patients (35 \%) and the median HbA1C was 7.0 \% (25th-75th percentile: 6.8-7.9 \%), equalling 53 mmol/mol (51, 63); 24.2 \% of patients received dietary treatment only, 25.5 \% oral antidiabetic drugs but not insulin, 8.4 \% oral antidiabetic drugs with insulin, and 41.8 \% insulin alone. Metformin was used by 18.8 \%. Factors associated with an HbA1C level >7.0 \% (53 mmol/mol) were higher BMI (OR = 1.04 per increase of 1 kg/m2, 95 \% CI 1.02-1.06), hemoglobin (OR = 1.11 per increase of 1 g/dL, 95 \% CI 1.04-1.18), treatment with insulin alone (OR = 5.63, 95 \% CI 4.26-7.45) or in combination with oral antidiabetic agents (OR = 4.23, 95 \% CI 2.77-6.46) but not monotherapy with metformin, DPP-4 inhibitors, or glinides. Conclusions Within the GCKD cohort of patients with CKD stage 3 or overt proteinuria, antidiabetic treatment patterns were highly variable with a remarkably high proportion of more than 50 \% receiving insulin-based therapies. Metabolic control was overall satisfactory, but insulin use was associated with higher HbA1C levels.},
  language  = {en}
}
@article{DienemannFujiiOrlandietal.2016,
  author    = {Dienemann, Thomas and Fujii, Naohiko and Orlandi, Paula and Nessel, Lisa and Furth, Susan L. and Hoy, Wendy E. and Matsuo, Seiichi and Mayer, Gert and Methven, Shona and Schaefer, Franz and Schaeffner, Elke S. and Sol{\´a}, Laura and Stengel, B{\´e}n{\´e}dicte and Wanner, Christoph and Zhang, Luxia and Levin, Adeera and Eckardt, Kai-Uwe and Feldman, Harold I.},
  title     = {International Network of Chronic Kidney Disease cohort studies (iNET-CKD): a global network of chronic kidney disease cohorts},
  series = {BMC Nephrology},
  volume    = {17},
  journal   = {BMC Nephrology},
  doi       = {10.1186/s12882-016-0335-2},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-164604},
  pages     = {121},
  year      = {2016},
  abstract  = {Background Chronic kidney disease (CKD) is a global health burden, yet it is still underrepresented within public health agendas in many countries. Studies focusing on the natural history of CKD are challenging to design and conduct, because of the long time-course of disease progression, a wide variation in etiologies, and a large amount of clinical variability among individuals with CKD. With the difference in health-related behaviors, healthcare delivery, genetics, and environmental exposures, this variability is greater across countries than within one locale and may not be captured effectively in a single study. Methods Studies were invited to join the network. Prerequisites for membership included: 1) observational designs with a priori hypotheses and defined study objectives, patient-level information, prospective data acquisition and collection of bio-samples, all focused on predialysis CKD patients; 2) target sample sizes of 1,000 patients for adult cohorts and 300 for pediatric cohorts; and 3) minimum follow-up of three years. Participating studies were surveyed regarding design, data, and biosample resources. Results Twelve prospective cohort studies and two registries covering 21 countries were included. Participants age ranges from >2 to >70 years at inclusion, CKD severity ranges from stage 2 to stage 5. Patient data and biosamples (not available in the registry studies) are measured yearly or biennially. Many studies included multiple ethnicities; cohort size ranges from 400 to more than 13,000 participants. Studies' areas of emphasis all include but are not limited to renal outcomes, such as progression to ESRD and death. Conclusions iNET-CKD (International Network of CKD cohort studies) was established, to promote collaborative research, foster exchange of expertise, and create opportunities for research training. Participating studies have many commonalities that will facilitate comparative research; however, we also observed substantial differences. The diversity we observed across studies within this network will be able to be leveraged to identify genetic, behavioral, and health services factors associated with the course of CKD. With an emerging infrastructure to facilitate interactions among the investigators of iNET-CKD and a broadly defined research agenda, we are confident that there will be great opportunity for productive collaborative investigations involving cohorts of individuals with CKD.},
  language  = {en}
}